Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

103 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CD19 occupancy with tafasitamab increases therapeutic index of CART19 cell therapy and diminishes severity of CRS.
Sakemura RL, Manriquez Roman C, Horvei P, Siegler EL, Girsch JH, Sirpilla OL, Stewart CM, Yun K, Can I, Ogbodo EJ, Adada MM, Bezerra ED, Kankeu Fonkoua LA, Hefazi M, Ruff MW, Kimball BL, Mai LK, Huynh TN, Nevala WK, Ilieva K, Augsberger C, Patra-Kneuer M, Schanzer J, Endell J, Heitmüller C, Steidl S, Parikh SA, Ding W, Kay NE, Nowakowski GS, Kenderian SS. Sakemura RL, et al. Among authors: steidl s. Blood. 2024 Jan 18;143(3):258-271. doi: 10.1182/blood.2022018905. Blood. 2024. PMID: 37879074 Free PMC article.
Activity of tafasitamab in combination with rituximab in subtypes of aggressive lymphoma.
Patra-Kneuer M, Chang G, Xu W, Augsberger C, Grau M, Zapukhlyak M, Ilieva K, Landgraf K, Mangelberger-Eberl D, Yousefi K, Berning P, Kurz KS, Ott G, Klener P, Khandanpour C, Horna P, Schanzer J, Steidl S, Endell J, Heitmüller C, Lenz G. Patra-Kneuer M, et al. Among authors: steidl s. Front Immunol. 2023 Jul 31;14:1220558. doi: 10.3389/fimmu.2023.1220558. eCollection 2023. Front Immunol. 2023. PMID: 37600821 Free PMC article.
Tafasitamab mediates killing of B-cell non-Hodgkin's lymphoma in combination with γδ T cell or allogeneic NK cell therapy.
Her JH, Pretscher D, Patra-Kneuer M, Schanzer J, Cho SY, Hwang YK, Hoeres T, Boxhammer R, Heitmueller C, Wilhelm M, Steidl S, Endell J. Her JH, et al. Among authors: steidl s. Cancer Immunol Immunother. 2022 Nov;71(11):2829-2836. doi: 10.1007/s00262-022-03165-w. Epub 2022 Mar 29. Cancer Immunol Immunother. 2022. PMID: 35348812 Free PMC article.
IL-17C amplifies epithelial inflammation in human psoriasis and atopic eczema.
Lauffer F, Jargosch M, Baghin V, Krause L, Kempf W, Absmaier-Kijak M, Morelli M, Madonna S, Marsais F, Lepescheux L, Albanesi C, Müller NS, Theis FJ, Schmidt-Weber C, Eyerich S, Biedermann T, Vandeghinste N, Steidl S, Eyerich K. Lauffer F, et al. Among authors: steidl s. J Eur Acad Dermatol Venereol. 2020 Apr;34(4):800-809. doi: 10.1111/jdv.16126. Epub 2020 Jan 19. J Eur Acad Dermatol Venereol. 2020. PMID: 31793105
Neutralization of IL-17C Reduces Skin Inflammation in Mouse Models of Psoriasis and Atopic Dermatitis.
Vandeghinste N, Klattig J, Jagerschmidt C, Lavazais S, Marsais F, Haas JD, Auberval M, Lauffer F, Moran T, Ongenaert M, Van Balen M, Dupont S, Lepescheux L, Garcia T, Härtle S, Eyerich K, Fallon PG, Brys R, Steidl S. Vandeghinste N, et al. Among authors: steidl s. J Invest Dermatol. 2018 Jul;138(7):1555-1563. doi: 10.1016/j.jid.2018.01.036. Epub 2018 Feb 21. J Invest Dermatol. 2018. PMID: 29474945 Free article.
Randomized phase 1b trial of MOR103, a human antibody to GM-CSF, in multiple sclerosis.
Constantinescu CS, Asher A, Fryze W, Kozubski W, Wagner F, Aram J, Tanasescu R, Korolkiewicz RP, Dirnberger-Hertweck M, Steidl S, Libretto SE, Sprenger T, Radue EW. Constantinescu CS, et al. Among authors: steidl s. Neurol Neuroimmunol Neuroinflamm. 2015 May 21;2(4):e117. doi: 10.1212/NXI.0000000000000117. eCollection 2015 Aug. Neurol Neuroimmunol Neuroinflamm. 2015. PMID: 26185773 Free PMC article.
103 results